Pharmacokinetic design optimization in children and estimation of maturation parameters: Example of cytochrome P450 3A4

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 38, Issue 1, 2011, Pages 25-40

  Bouillon Pichault, Marion ^a,b,c,d,h   Jullien, Vincent ^a,b,c,d   Bazzoli, Caroline ^b   Pons, Gérard ^a,b,c,d   Tod, Michel ^e,f,g  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c RIPPS Network   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ DE LYON   (France)

^f UNIVERSITÉ LYON 1   (France)

^g CROIX ROUSSE HOSPITAL   (France)

^h Institut Cochin   (France)

Author keywords

Children; Maturation function; Population pharmacokinetics; Protocol optimisation

Indexed keywords

CYTOCHROME P450 3A4; MIDAZOLAM;

ACCURACY; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; ENZYME ACTIVITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEASUREMENT ERROR; PHARMACOKINETICS; POPULATION MODEL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SAMPLING ERROR; WEIGHT CHANGE;

ADULT; AGE FACTORS; AREA UNDER CURVE; CHILD; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP3A; HUMANS; INFANT; INFANT, NEWBORN; LINEAR MODELS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACOKINETICS; RESEARCH DESIGN; TIME FACTORS;

EID: 79551596429     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-010-9173-1     Document Type: Article

References (37)

1. GL Kearns SM Abdel-Rahman SW Alander DL Blowey JS Leeder RE Kauffman 2003 Developmental pharmacology-drug disposition, action, and therapy in infants and children N Engl J Med 349 1157 1167 1:CAS:528:DC%2BD3sXnsV2jtbo%3D 10.1056/NEJMra035092 13679531
2. GA Chalkiadis BJ Anderson 2006 Age and size are the major covariates for prediction of levobupivacaine clearance in children Paediatr Anaesth 16 275 282 10.1111/j.1460-9592.2005.01778.x 16490091
3. S Bjorkman 2006 Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods? Clin Pharmacokinet 45 1 11 10.2165/00003088-200645010-00001 16430308
4. AN Edginton W Schmitt S Willmann 2006 Development and evaluation of a generic physiologically based pharmacokinetic model for children Clin Pharmacokinet 45 1013 1034 1:CAS:528:DC%2BD28XhtF2rurzP 10.2165/00003088- 200645100-00005 16984214
5. AN Edginton W Schmitt B Voith S Willmann 2006 A mechanistic approach for the scaling of clearance in children Clin Pharmacokinet 45 683 704 1:CAS:528:DC%2BD28Xot1eksLs%3D 10.2165/00003088-200645070-00004 16802850
6. BJ Anderson NH Holford 2008 Mechanism-based concepts of size and maturity in pharmacokinetics Annu Rev Pharmacol Toxicol 48 303 332 1:CAS:528: DC%2BD1cXisFynu7g%3D 10.1146/annurev.pharmtox.48.113006.094708 17914927
7. TN Johnson A Rostami-Hodjegan GT Tucker 2006 Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children Clin Pharmacokinet 45 931 956 1:CAS:528:DC%2BD28XhtVGisrvN 10.2165/00003088- 200645090-00005 16928154
8. EMEA (2006) Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003066.pdf
9. M Tod V Jullien G Pons 2008 Facilitation of drug evaluation in children by population methods and modelling Clin Pharmacokinet 47 231 243 1:CAS:528:DC%2BD1cXltl2ntLg%3D 10.2165/00003088-200847040-00002 18336053
10. BJ Anderson K Allegaert NH Holford 2006 Population clinical pharmacology of children: modelling covariate effects Eur J Pediatr 165 819 829 10.1007/s00431-006-0189-x 16807729
11. I Gueorguieva K Ogungbenro G Graham S Glatt L Aarons 2007 A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models Comput Methods Programs Biomed 86 51 61 10.1016/j.cmpb.2007.01.004 17292995
12. S Hennig TH Waterhouse SC Bell, et al. 2007 A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients Br J Clin Pharmacol 63 438 450 1:CAS:528:DC%2BD2sXlt1ahurw%3D 10.1111/j.1365-2125.2006.02778.x 17073891
13. Bazzoli C, Retout S, Comets E and Mentré F (2008) INSERM U, Université Paris 7, Paris, France. PFIM 3.0. Available at: http://www.pfim.biostat.fr/Read-me-PFIM3.0.pdf
14. Bazzoli C, Retout S, Mentré F (2009) Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Comput Methods Programs Biomed 98(1):55-65
15. F Mentre F A Mallet D Baccar 1997 Optimal design in random-effects regression models Biometrika 84 429 442 10.1093/biomet/84.2.429
16. S Retout E Comets A Samson F Mentre 2007 Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates Stat Med 26 5162 5179 10.1002/sim.2910 17486667
17. S Retout F Mentre 2003 Optimization of individual and population designs using Splus J Pharmacokinet Pharmacodyn 30 417 443 10.1023/B:JOPA.0000013000. 59346.9a 15000423
18. S Langlois JH Kreeft G Chouinard A Ross-Chouinard S East RI Ogilvie 1987 Midazolam: kinetics and effects on memory, sensorium, and haemodynamics Br J Clin Pharmacol 23 273 278 1:CAS:528:DyaL2sXhvVyqsb0%3D 3567042
19. PJ Pentikainen L Valisalmi JJ Himberg C Crevoisier 1989 Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects J Clin Pharmacol 29 272 277 1:STN:280:DyaL1M3ls1Smuw%3D%3D 2723115
20. S Sjovall J Kanto JJ Himberg M Hovi-Viander M Salo 1983 CSF penetration and pharmacokinetics of midazolam Eur J Clin Pharmacol 25 247 251 1:STN:280:DyaL2c%2FivVyhtQ%3D%3D 10.1007/BF00543799 6628509
21. S Chhun V Jullien E Rey O Dulac C Chiron G Pons 2009 Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy Epilepsia 50 1150 1157 1:CAS:528:DC%2BD1MXms1Skt7w%3D 10.1111/j.1528-1167.2008.01974.x 19175400
22. T Kerbusch U Wahlby PA Milligan MO Karlsson 2003 Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability Br J Clin Pharmacol 56 639 652 1:CAS:528:DC%2BD2cXivFSmsw%3D%3D 10.1046/j.1365-2125.2003.01967.x 14616424
23. MY Peeters SA Prins CA Knibbe, et al. 2006 Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery Anesthesiology 105 1135 1146 1:CAS:528:DC%2BD28Xht1CgtLvN 10.1097/00000542-200612000-00013 17122576
24. H Mulla P McCormack G Lawson RK Firmin DR Upton 2003 Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation Anesthesiology 99 275 282 1:CAS:528:DC%2BD3sXlvVSgsLg%3D 10.1097/00000542- 200308000-00008 12883399
25. Beal SL and Sheiner LB, (eds) (1991) NONMEM user's guide, University of California at San Francisco, NONMEM Pproject Group, San Francisco
26. LB Sheiner SL Beal 1981 Some suggestions for measuring predictive performance J Pharmacokinet Biopharm 9 503 512 1:STN:280:DyaL38%2FnslGruw%3D%3D 10.1007/BF01060893 7310648
27. K Brendel C Dartois E Comets, et al. 2007 Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004 Clin Pharmacokinet 46 221 234 10.2165/00003088-200746030-00003 17328581
28. B Green SB Duffull 2003 Prospective evaluation of a D-optimal designed population pharmacokinetic study J Pharmacokinet Pharmacodyn 30 145 161 1:CAS:528:DC%2BD3sXms1yhtLs%3D 10.1023/A:1024467714170 12942685
29. LK van Rossum RA Mathot K Cransberg AG Vulto 2003 Optimal sampling strategies to assess inulin clearance in children by the inulin single-injection method Clin Chem 49 1170 1179 10.1373/49.7.1170 12816915
30. PK Turner LC Iacono JC Panetta, et al. 2006 Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children Cancer Chemother Pharmacol 57 475 482 1:CAS:528:DC%2BD28XjtVyiuw%3D%3D 10.1007/s00280-005-0062-z 16047146
31. BJ Anderson K Allegaert JN Van den Anker V Cossey NH Holford 2007 Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance Br J Clin Pharmacol 63 75 84 1:CAS:528:DC%2BD2sXhsFWqu78%3D 10.1111/j.1365-2125.2006.02725.x 16869817
32. M Tod F Lokiec R Bidault F De Bony O Petitjean Y Aujard 2001 Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis Antimicrob Agents Chemother 45 150 157 1:CAS:528:DC%2BD3MXhsFGjug%3D%3D 10.1128/AAC.45.1.150-157.2001 11120958
33. JC Gorski SD Hall DR Jones M VandenBranden SA Wrighton 1994 Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily Biochem Pharmacol 47 1643 1653 1:CAS:528: DyaK2cXksV2mtLg%3D 10.1016/0006-2952(94)90543-6 8185679
34. CB Eap T Buclin E Hustert, et al. 2004 Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects Eur J Clin Pharmacol 60 231 236 1:CAS:528:DC%2BD2cXltVKmt7Y%3D 15114431
35. ER Lepper SD Baker M Permenter, et al. 2005 Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients Clin Cancer Res 11 7398 7404 1:CAS:528:DC%2BD2MXhtFartbvM 10.1158/1078-0432.CCR-05-0520 16243813
36. M Chenel F Bouzom L Aarons K Ogungbenro 2008 Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes J Pharmacokinet Pharmacodyn 35 635 659 1:CAS:528:DC%2BD1MXpvVeluw%3D%3D 10.1007/s10928-008-9104-6 19130188
37. R Hyland T Osborne A Payne, et al. 2009 In vitro and in vivo glucuronidation of midazolam in humans Br J Clin Pharmacol 67 445 454 1:CAS:528:DC%2BD1MXlvFSju78%3D 10.1111/j.1365-2125.2009.03386.x 19371318